Leukaemias & myeloproliferative neoplasms (overview)
Haematology · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Leukaemias are clonal haematopoietic malignancies. Acute leukaemias (AML, ALL) present rapidly with marrow failure and are emergencies; chronic leukaemias and myeloproliferative neoplasms are more indolent.
Red flags
- Blasts on film, pancytopenia, febrile neutropenia, suspected APL or tumour lysis are emergencies - admit and call haematology same day
- Routine urgent referral for persistent lymphocytosis, unexplained cytopenias, splenomegaly or sustained erythrocytosis/thrombocytosis
Assessment
Investigations
- FBC and blood film (blasts, Auer rods in AML, smear cells in CLL, left shift in CML)
- Bone marrow aspirate/trephine with immunophenotyping (flow), cytogenetics and molecular (BCR-ABL1, NPM1, FLT3, JAK2, CALR)
- LDH, urate, coagulation (DIC risk in APL)
- Lumbar puncture in ALL
- Flow cytometry diagnostic for CLL
Management
- Acute: urgent haematology - intensive induction chemotherapy;
- APL (AML M3) uses all- trans retinoic acid + arsenic trioxide (medical emergency)
- Allogeneic transplant for high- risk
- CML: tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib)
- CLL: watch-and-wait if asymptomatic, else BTK inhibitors (ibrutinib/acalabrutinib) or venetoclax +/- anti-CD20
- MPN: aspirin + venesection (PV), cytoreduction (hydroxycarbamide), JAK inhibitor (ruxolitinib) for myelofibrosis
Disposition
Blasts on film, pancytopenia, febrile neutropenia, suspected APL or tumour lysis are emergencies - admit and call haematology same day.
Complications & pitfalls
- Febrile neutropenia and sepsis, tumour lysis syndrome, DIC (especially APL), leucostasis/hyperviscosity, thrombosis/haemorrhage in MPN, transformation (CML blast crisis, MPN to AML, Richter transformation of CLL)
- Treatment toxicity, infection and prolonged cytopenias
Exam pearls
- Suspected acute promyelocytic leukaemia (APL: pancytopenia with DIC and coagulopathy) is a true emergency - start ATRA immediately on clinical suspicion before genetic confirmation, as early death is from haemorrhage.
- Monitoring & follow-up: Monitor FBC, blasts and chimerism post-transplant. CML: molecular monitoring of BCR-ABL1 transcripts to assess TKI response. MPN: counts, spleen, thrombotic symptoms, haematocrit target <0.45 in PV. CLL: counts and symptoms. Vigilance for infection and secondary malignancy; vaccination and prophylaxis as indicated.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.